MA41629A - Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité - Google Patents

Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité

Info

Publication number
MA41629A
MA41629A MA041629A MA41629A MA41629A MA 41629 A MA41629 A MA 41629A MA 041629 A MA041629 A MA 041629A MA 41629 A MA41629 A MA 41629A MA 41629 A MA41629 A MA 41629A
Authority
MA
Morocco
Prior art keywords
infertility
compositions
treatment
methods
müllerian hormone
Prior art date
Application number
MA041629A
Other languages
English (en)
Inventor
Norbert Gleicher
Vitaly A Kushnir
Aritro Sen
Original Assignee
Center For Human Reproduction
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center For Human Reproduction, Univ Rochester filed Critical Center For Human Reproduction
Publication of MA41629A publication Critical patent/MA41629A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA041629A 2015-03-04 2016-02-28 Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité MA41629A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562128127P 2015-03-04 2015-03-04

Publications (1)

Publication Number Publication Date
MA41629A true MA41629A (fr) 2018-01-09

Family

ID=55538624

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041629A MA41629A (fr) 2015-03-04 2016-02-28 Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité

Country Status (5)

Country Link
US (1) US10478473B2 (fr)
EP (1) EP3265111A2 (fr)
CA (1) CA2978005A1 (fr)
MA (1) MA41629A (fr)
WO (1) WO2016140910A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112739372A (zh) * 2018-09-28 2021-04-30 美国西门子医学诊断股份有限公司 用于稳定纯化的苗勒氏管抑制物质(mis)的储存溶液组合物和与其相关的使用和生产方法
CA3139956A1 (fr) 2019-05-31 2020-12-03 Laura DETTI Peptides se liant au recepteur de l'hormone anti-mullerienne
CN110938657A (zh) * 2019-12-25 2020-03-31 中国大熊猫保护研究中心 重组表达大熊猫促黄体生成素的载体、表达系统及制备方法
KR102316507B1 (ko) * 2020-02-28 2021-10-22 차의과학대학교 산학협력단 난소 예비력 바이오마커 및 이의 용도
EP3888666A1 (fr) 2020-04-03 2021-10-06 InoCells B.V. Composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4753794A (en) * 1986-06-24 1988-06-28 The General Hospital Corporation Use of mullerian inhibiting substance as a contraceptive agent
WO1989009622A1 (fr) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Anticorps chimeriques specifiques au recepteur il-2
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5484768A (en) 1990-05-16 1996-01-16 The University Of Melbourne Treatment of male infertility by administration of a muellerian inhibiting substance and surgery and/or hormonal treatment
CA2087026A1 (fr) 1990-05-16 1992-01-11 Patricia K. Donahoe Traitement de l'infertilite masculine
ES2061416T3 (es) 1990-10-12 1997-03-01 Max Planck Gesellschaft Ribozimas modificadas.
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
CA2150803C (fr) 1992-12-02 2006-01-31 Henry Auer Hormone de croissance a liberation controlee qui contient des microspheres
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
PT831787E (pt) 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6103489A (en) 1997-03-21 2000-08-15 University Of Hawaii Cell-free protein synthesis system with protein translocation and processing
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6416779B1 (en) 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR100413150B1 (ko) 1998-09-10 2003-12-31 에프. 호프만-라 로슈 아게 5-에이치티4 수용체 길항제로서의 디하이드로벤조디옥신 카복스아미드 및 케톤 유도체
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof
EP1074265A1 (fr) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Utilisation de l'AMH et/ou d'un agoniste de l'AMH et/ou d'un antagoniste de l'AMH pour contoler la fertilité féminine à long terme
US6258819B1 (en) 1999-08-05 2001-07-10 Syntex (U.S.A.) Llc Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6515198B2 (en) 2000-02-15 2003-02-04 Syntex (U.S.A.) Llc Use of purinergic receptor modulators and related reagents
EP1289964B1 (fr) 2000-05-25 2004-10-20 F. Hoffmann-La Roche Ag 1-aminoalkyle-lactames substitues et leur utilisation en tant qu'antagonistes de recepteur muscarinique
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US6417186B1 (en) 2000-11-14 2002-07-09 Syntex (U.S.A.) Llc Substituted-phenyl ketone derivatives as IP antagonists
CA2457918C (fr) * 2001-08-20 2013-11-26 David B. Seifer Taux de substance d'inhibition du canal de muller (mis) et reponse ovarienne
EP1986676A4 (fr) 2006-02-15 2009-11-04 Univ Yale Inc Compositions et procedes utilisant des fragments de peptide du facteur derive d'epithelium pigmentaire (pedf)
WO2009052119A1 (fr) 2007-10-14 2009-04-23 Columbia University Procédé de traitement de l'endométriose par administration d'hormone anti-müllérienne
WO2011045202A1 (fr) 2009-10-12 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagoniste ou agoniste sélectif de amhrii pour moduler la fertilité
WO2011109415A2 (fr) 2010-03-02 2011-09-09 Amgen Inc. Réduction de la viscosité de formulations pharmaceutiques
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
US20120046228A1 (en) 2010-08-18 2012-02-23 University Of Medicine And Dentistry Of New Jersey Methods for Modulating Ovulation
ITRM20120285A1 (it) * 2012-06-18 2013-12-19 Alfonso Baldi Ormone anti-mulleriano.
PL2968470T3 (pl) * 2013-03-12 2021-05-31 The General Hospital Corporation Zmodyfikowane białka stanowiące substancję hamującą rozwój przewodów müllera (mis) i ich zastosowania do leczenia chorób
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
ES2912283T3 (es) 2013-12-11 2022-05-25 Massachusetts Gen Hospital Uso de proteínas de tipo sustancia inhibidora mülleriana (SIM) para la anticoncepción y conservación de la reserva ovárica
US20170239333A1 (en) 2014-08-31 2017-08-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods for preventing premature follicle activation
US10175252B2 (en) * 2016-02-04 2019-01-08 American Infertility Of New York, P.C. Diagnosis, and anti-mullerian hormone (AMH) administration for treatment, of infertility for good-, intermediate- and poor-prognosis patients for in vitro fertilization in view of logistic regression models

Also Published As

Publication number Publication date
EP3265111A2 (fr) 2018-01-10
US20180236034A1 (en) 2018-08-23
WO2016140910A3 (fr) 2016-10-27
WO2016140910A2 (fr) 2016-09-09
CA2978005A1 (fr) 2016-09-09
US10478473B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
EP3390357A4 (fr) Composés de biarylmonobactame et procédés d'utilisation correspondants pour le traitement d'infections bactériennes
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l'anxiété et de la dépression
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3848022C0 (fr) Agent thérapeutique pour utilisation dans le traitement d'infections
EP3688023A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3638293A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
EP3365014A4 (fr) Méthodes et compositions pour le traitement de la mastocytose systémique